Brokerage firm PiperJaffray Upgrades its rating on Regeneron Pharmaceuticals Inc(REGN). The shares have been rated Overweight. Previously, the analysts had a Neutral rating on the shares. The rating by the stock financial advisor at PiperJaffray was issued on Feb 13, 2017 in a research report to their Investors and Clients.
In a different note, BMO Capital said it Initiates Coverage On Regeneron Pharmaceuticals Inc, according to a research note issued on Dec 20, 2016. In the research note, the firm Announces the price-target to $419 per share. The shares have been rated ‘Market Perform’ by the firm. On Dec 16, 2016, BTIG Research said it Upgrades its rating on Regeneron Pharmaceuticals Inc. In the research note, the firm Announces the price-target to $460 per share. The shares have been rated ‘Buy’ by the firm. On Dec 12, 2016, Chardan Capital said it Upgrades its rating on Regeneron Pharmaceuticals Inc. According to the research note, Chardan Capital Raises the price target to $350 per share from a prior target of $300. The shares have been rated ‘Neutral’ by the firm.
Regeneron Pharmaceuticals Inc (REGN) shares turned negative on Wednesdays trading session with the shares closing down -1.39 points or -0.37% at a volume of 5,69,426. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $373.1599. The peak price level was also seen at $373.1599 while the days lowest was $369.12. Finally the shares closed at $370.22. The 52-week high of the shares is $452.96 while the 52-week low is $325.35. According to the latest information available, the market cap of the company is $39,273 M.
Regeneron Pharmaceuticals Inc(REGN) last announced its earnings results on Feb 9, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $1.227B. Analysts had an estimated revenue of $1.310B. Earnings per share were $3.04. Analysts had estimated an EPS of $3.1.
Several Insider Transactions has been reported to the SEC. On Dec 14, 2016, Charles A Baker (director) sold 3,000 shares at $392.48 per share price.Also, On Nov 16, 2016, Arthur F Ryan (director) sold 2,000 shares at $429.34 per share price.On Nov 15, 2016, Joseph L Goldstein (director) sold 2,125 shares at $450.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.